Physician profile
Robert V Clampitt
NPI 1225090509
$8,499.36
in general payments reported to CMS, 2019-2025
51 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $928 · 2021: $1,088 · 2022: $1,483 · 2023: $1,260 · 2024: $1,355 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,772.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,581.33 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $876.90 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $704.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Janssen Pharmaceuticals, INC | $612.48 | 2019-2023 | Spravato |
| Abbvie INC. | $547.42 | 2020-2025 | Vraylar, Ubrelvy, Creon |
| Otsuka America Pharmaceutical, INC. | $437.44 | 2023-2025 | Rexulti, Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $379.27 | 2021-2024 | |
| Amgen INC. | $335.00 | 2020-2024 | Otezla, Repatha |
| Lilly USA, LLC | $292.56 | 2019-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $269.76 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $206.76 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $144.18 | 2019-2022 | |
| Allergan, INC. | $139.83 | 2019-2020 | |
| Mylan Specialty L.P. | $128.56 | 2020-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.47 | 2023-2025 | Xifaxan |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Clampitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.